Previous Article | Next Article 
Molecular and Cellular Biology, March 1999, p. 2169-2179, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Reduced Phosphorylation of p50 Is Responsible for
Diminished NF-
B Binding to the Major Histocompatibility
Complex Class I Enhancer in Adenovirus Type
12-Transformed Cells
David B.
Kushner1,2,
and
Robert P.
Ricciardi1,3,*
Department of Microbiology, School of Dental
Medicine,1 Graduate Group in Cell and
Molecular Biology,2 and Department of
Biochemistry and Biophysics, School of
Medicine,3 University of Pennsylvania,
Philadelphia, Pennsylvania 19104
Received 13 July 1998/Returned for modification 24 August
1998/Accepted 18 November 1998
 |
ABSTRACT |
Reduced cell surface levels of major histocompatibility complex
class I antigens enable adenovirus type 12 (Ad12)-transformed cells to
escape immunosurveillance by cytotoxic T lymphocytes (CTL),
contributing to their tumorigenic potential. In contrast, nontumorigenic Ad5-transformed cells harbor significant cell surface levels of class I antigens and are susceptible to CTL lysis. Ad12 E1A
mediates down-regulation of class I transcription by increasing COUP-TF
repressor binding and decreasing NF-
B activator binding to the class
I enhancer. The mechanism underlying the decreased binding of nuclear
NF-
B in Ad12-transformed cells was investigated. Electrophoretic
mobility shift assay analysis of hybrid NF-
B dimers reconstituted
from denatured and renatured p50 and p65 subunits from Ad12- and
Ad5-transformed cell nuclear extracts demonstrated that p50, and not
p65, is responsible for the decreased ability of NF-
B to bind to DNA
in Ad12-transformed cells. Hypophosphorylation of p50 was found to
correlate with restricted binding of NF-
B to DNA in Ad12-transformed
cells. The importance of phosphorylation of p50 for NF-
B binding was
further demonstrated by showing that an NF-
B dimer composed of p65
and alkaline phosphatase-treated p50 from Ad5-transformed cell nuclear
extracts could not bind to DNA. These results suggest that
phosphorylation of p50 is a key step in the nuclear regulation of
NF-
B in adenovirus-transformed cells.
 |
INTRODUCTION |
All human adenoviruses are able to
transform nonpermissive rodent cells in vitro. The viral E1A and E1B
transforming genes are responsible for disruption of the cell cycle and
prevention of apoptosis (reviewed in reference 56).
Interestingly, only a subset of adenovirus serotypes, including
adenovirus type 12 (Ad12), can induce the formation of tumors in
immunocompetent rodents following inoculation of virus or transformed
cells. The highly tumorigenic phenotype of Ad12 correlates with a sharp
decrease in cell surface levels of the major histocompatibility complex (MHC) class I antigens (11, 17, 59). The diminished class I
antigen expression on Ad12-transformed cells enables them to escape
detection by cytotoxic T lymphocytes (CTL) and contributes to their
tumorigenic potential (11, 63, 70). In contrast, significant
cell surface expression of class I antigens on nontumorigenic Ad5-transformed cells allows for CTL recognition and lysis.
E1A is the only gene of Ad12 required for down-regulated synthesis of
class I antigens (67). The block in the expression of class
I antigens is at the level of transcription (1, 20), and the
47-bp class I enhancer is the target of this transcriptional down-regulation (21, 32) (Fig.
1). In Ad12-transformed cells, the orphan
nuclear hormone receptor COUP-TF is strongly bound to the R2 site of
the enhancer (39). Additionally, the transcriptional activator NF-
B is weakly bound to the R1 site of the enhancer in
Ad12-transformed cells (2, 38, 43, 46). The increased binding of COUP-TF and the decreased binding of NF-
B to the enhancer are mediated by the first exon (residues 1 to 144) of Ad12 E1A (33). In direct contrast, active class I transcription in
Ad5-transformed cells can be accounted for by the strong binding of
NF-
B and the weak binding of COUP-TF to their respective recognition
elements in the enhancer.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Regulation of the MHC class I promoter in
adenovirus-transformed cells. Transcription of class I genes is greatly
reduced in Ad12- versus Ad5-transformed cells because of increased
binding of the COUP-TF repressor to the R2 site and decreased binding
of the NF- B activator to the R1 site of the enhancer. Diminished MHC
class I levels correlate with tumorigenic potential. Arrow,
transcriptional start site; closed circle, TATA box; gray rectangle,
interferon response element (IRS); black rectangle,
H-2Kb class I enhancer.
|
|
The reason for the decreased binding of NF-
B to the class I enhancer
in Ad12-transformed cells is not fully understood. NF-
B is a dimer
composed of proteins of the Rel family (reviewed in references
8, 42, 45, and
64). The transcriptionally active form of NF-
B is
a heterodimer (66) of the p50 (NF-
B1-p50) subunit
(12, 23, 30, 44) and the p65 (RelA) subunit (47, 57), which contains the transactivation domain (10, 54, 58). Typically, NF-
B is sequestered in the cytoplasm by an I
B (reviewed in reference 69). Stimulation of
cells with various inducers, such as cytokines, phorbol esters, or
growth factors, causes I
B to be phosphorylated by means of a complex
kinase cascade (reviewed in reference 62) and
degraded by the 26S proteasome (3, 14, 15, 37, 50, 65). As a
consequence, cytoplasmic NF-
B becomes free to translocate to the nucleus.
However, in adenovirus-transformed cells, the p50 and p65 subunits of
NF-
B are constitutively present in the nucleus (38). In
Ad5-transformed cells, NF-
B binds to the R1 site of the class I
enhancer, activating class I expression (2, 9, 27, 38, 43, 46, 55,
60). Intriguingly, in Ad12-transformed cells, NF-
B binding to
the R1 site is greatly diminished, contributing to the down-regulation
of class I transcription. In Ad12- and Ad5-transformed cells, this
differential ability of NF-
B to bind to the R1 site cannot be
accounted for by a difference in the levels of NF-
B, since the
amounts of nuclear p50 and p65, respectively, are approximately equal
in these cells (33, 38).
In this paper, we demonstrate that the p50 subunit of the NF-
B dimer
is responsible for the decreased binding observed in Ad12-transformed
cells. In addition, we provide evidence that hypophosphorylation of the
p50 subunit is responsible for the decreased binding phenotype.
 |
MATERIALS AND METHODS |
Cell lines.
The Ad5 (DP5-2) and Ad12 (12-1) E1-transformed
Hooded Lister rat cell lines were constructed previously (28,
29). Monolayer cultures of cells were grown in minimal essential
medium
(GIBCO-BRL) supplemented with 10% fetal bovine serum
(HyClone), 2 mM L-glutamine, 100 U of penicillin per
ml, 0.1 mg of streptomycin per ml, and 2.5 µg of amphotericin B
(Fungizone) per ml.
Nuclear extract preparation.
Nuclear extracts of DP5-2 and
12-1 cells were prepared as described previously (33) with
slight modifications. Briefly, cells were harvested by trypsinization,
washed in phosphate-buffered saline, and lysed in 2 packed-cell volumes
of Triton lysis buffer (9 mM Tris-HCl [pH 7.5], 135 mM NaCl, 0.9 mM
MgCl2, 0.5 mM dithiothreitol [DTT], 0.5 mM
phenylmethylsulfonyl fluoride [PMSF], and either 0.3% Triton X-100
[DP5-2 cells] or 0.35% Triton X-100 [12-1 cells]) for 4 to 6 min
on ice. Nuclei were pelleted at 1,000 × g for 5 min at
4°C, washed once in Triton lysis buffer lacking Triton X-100, and
then resuspended in 2 packed-cell volumes of Dignam buffer C (25%
glycerol, 20 mM HEPES [pH 7.9], 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT
[16]). Nuclear proteins were extracted by mixing at
4°C for 45 min. Insoluble material was pelleted at 16,000 × g for 15 min at 4°C, and the supernatant was dialyzed for
1 h at 4°C against Shapiro's buffer D (20 mM HEPES [pH 7.9],
20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM EGTA, 2 mM DTT, 0.5 mM
PMSF, 0.5 mg of leupeptin per liter, 0.7 mg of pepstatin A per liter
[61]). Precipitated proteins were removed by
centrifugation at 12,000 × g for 15 min at 4°C, and
the supernatant was stored in aliquots at
80°C. For phosphatase experiments, nuclear extracts were isolated in buffers lacking phosphatase inhibitors.
Western blots and antisera.
Ten micrograms of nuclear
extract in sodium dodecyl sulfate (SDS) sample buffer (100 mM Tris-HCl
[pH 6.8], 4% SDS, 0.2% bromophenol blue, 200 mM DTT, 20% glycerol)
was boiled and electrophoresed on SDS-polyacrylamide gels. Separated
proteins were transferred to Immobilon-P membranes (Millipore) by
electroblotting. Membranes were blocked in 0.05% TBS-Tween (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 0.05% Tween 20) with 5% powdered
milk (Carnation) for at least 1 h. Membranes were incubated for
1 h with primary antibody (see below) and then washed three times
with 0.05% TBS-Tween. For detection of proteins by enhanced
chemiluminescence, membranes were incubated for 1 h with goat
anti-rabbit immunoglobulin G-horseradish peroxidase (Boehringer
Mannheim Biochemicals), washed three times with 0.05% TBS-Tween and
once with TBS (20 mM Tris-HCl [pH 7.5], 150 mM NaCl), and then
exposed to enhanced chemiluminescence reagents (Amersham). For
detection of proteins by 125I-conjugated secondary
antibody, membranes were washed once with 0.01% TBS-Tween, incubated
for 1 h with 1.5 µCi of goat anti-rabbit immunoglobulin G (heavy
and light) chains (ICN) per ml, washed three times with 0.01%
TBS-Tween and once with TBS, and then exposed overnight on a
PhosphorImager screen (Molecular Dynamics). The following peptide
antibodies (kind gifts of Nancy Rice) were used in these studies: 1157, anti-p50; 1613, anti-p50; and 1226, anti-p65. YY1 antibody sc-281 was
from Santa Cruz Biotechnology.
Two-dimensional gel electrophoresis.
Two-dimensional gel
electrophoresis of nuclear extracts from DP5-2 and 12-1 cells was
performed by the method of O'Farrell (48) by Kendrick Labs,
Inc. (Madison, Wis.). Proteins were run in the first dimension on
isoelectric focusing gels containing 2% pH 3.5 to 10 ampholines
(BDH-Hoefer) for 9,600 V · h and in the second dimension on a
10% polyacrylamide gel (0.75 mm thick) for about 4 h at 12.5 mA/gel. Electroblotting of proteins to polyvinylidene difluoride paper
in transfer buffer (12.5 mM Tris [pH 8.8], 86 mM glycine, 10%
methanol) was done overnight at 200 mA. Molecular weight standards were
from Sigma.
Denaturation-renaturation and analysis of NF-
B subunits.
Denaturation-renaturation of protein was performed essentially as
described previously (24, 66) with modifications. Nuclear extracts from DP5-2 and 12-1 cells were isolated as described above,
except that the proteins were dialyzed against Shapiro's buffer D
lacking glycerol and were concentrated at 4°C with a Centricon-30
(Amicon) to ca. 10 mg/ml, as determined by a modified Bradford assay
(Bio-Rad). Equivalent milligram amounts of DP5-2 and 12-1 nuclear
extracts were separated on SDS-8% polyacrylamide gels; with
prestained molecular weight markers (Bio-Rad and New England Biolabs)
as a guide, regions of the gels corresponding to 50 kDa (p50) and 65 kDa (p65) were excised and macerated. Protein was eluted overnight at
4°C in 350 µl of elution buffer (50 mM Tris [pH 8.0], 0.1% SDS,
0.1 mg of bovine serum albumin [BSA] per ml, 0.2 mM EDTA, 2.5%
glycerol, 1 mM DTT, 0.1 mM PMSF). Two percent of the eluate was
retained for Western analysis to verify the recovery of NF-
B
subunits from the gel slice. For phosphatase experiments, the eluate
was divided and treated with 8 U of calf intestinal alkaline
phosphatase (CIP) in the absence or presence of 2 mM sodium
orthovanadate, 20 mM NaF, and 1 mM EDTA for 30 min at 37°C. The
eluate was precipitated with 4 volumes of acetone overnight at
20°C
to remove SDS. The precipitate was pelleted, washed with
20°C
methanol, and dissolved in 10 µl of 6 M urea with 2 mM DTT. Suspended
50-kDa (p50) and 65-kDa (p65) proteins were mixed together in various
combinations to form NF-
B and then diluted 50-fold by the addition
of 1.375× renaturation buffer (1.375× electrophoretic mobility shift
assay [EMSA] binding buffer [10 mM Tris-HCl {pH 7.5}, 100 mM
NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol], 7% Shapiro's buffer D,
0.01 mM PMSF). After 2 h of renaturation at 4°C, 2% of the
renatured protein was quantitated by 125I Western analysis
to analyze the composition of NF-
B in each sample. After 24 h
of renaturation, protein was concentrated in a Microcon-10 (Amicon)
spin column and used as 73% of the final volume of an EMSA reaction
mixture containing 1 µg of poly(dI-dC) and 30,000 cpm of
32P-labeled double-stranded R1 oligonucleotide probe.
Reaction mixtures were incubated at 30°C for 30 min and
electrophoresed on a 5% nondenaturing polyacrylamide gel in 0.5× TBE
buffer (45 mM Tris-HCl [pH 8.3], 45 mM boric acid, 0.5 mM EDTA).
Dried gels were analyzed with a PhosphorImager and exposed to film.
For deoxycholate (DOC) experiments, after the 30-min EMSA reaction was
completed, DOC was added to 0.8% and then Nonidet P-40 (NP-40) was
added to 0.2%. After 10 min at room temperature, NP-40 was added to
1%. Five minutes later, samples were electrophoresed.
For supershift analysis, 3 µl of peptide antibody was added to
reaction mixtures 15 min prior to the addition of the labeled
probe.
All denaturation-renaturation experiments were repeated
at least three
times; the results shown are
representative.
Immunoprecipitation analysis.
Monolayer cultures of cells
were labeled for 16 to 20 h with 200 µCi of
32Pi (Amersham) per ml. Cells were harvested,
washed, and lysed for 20 min at 4°C in buffer X with BSA (50 mM Tris
[pH 8.8], 250 mM NaCl, 1% NP-40, 2 mM EDTA, 2 mg of BSA per ml) and
phosphatase and protease inhibitors (250 mM
Na3VO4, 50 mM NaF, and 2 mg of aprotinin per
ml). Lysates were clarified by centrifugation, normalized by counts per
minute, and precleared with protein A for 1 h. Precleared lysates
were subjected to primary immunoprecipitation for 4 h, protein A
beads were added, and immunocomplexes were collected for 2 h.
Beads were washed, and immunoprecipitated protein was released in 100 µl of denaturing buffer (50 mM Tris [pH 7.5], 0.5% SDS, 70 mM
-mercaptoethanol) at 95°C for 7 min. The supernatant was diluted
eightfold with RIPA buffer (50 mM Tris [pH 7.2], 150 mM NaCl, 0.1%
SDS, 1% DOC, 1% Triton X-100) with phosphatase and protease
inhibitors, and sequential immunoprecipitation was performed at 4°C
overnight. Protein A beads were added, and immunocomplexes were
collected for 2 h. Beads were washed and boiled in SDS sample buffer, and the supernatant was analyzed by polyacrylamide gel electrophoresis (PAGE). Dried gels were autoradiographed.
 |
RESULTS |
NF-
B binding to the R1 element of the MHC class I enhancer is
diminished in tumorigenic Ad12- compared to nontumorigenic Ad5-transformed cells (2, 33, 38, 43, 46). This differential binding of NF-
B between the two cell lines is not due to significant variations in the levels of nuclear p50 or p65 (33, 38). As originally observed (38), treatment of Ad12-transformed cell nuclear extracts with DOC dramatically increased NF-
B binding to the
R1 element, as observed by EMSA (see Fig. 4, compare lanes 1 and 2).
This result suggested that DOC might selectively remove a nuclear
inhibitor of NF-
B without perturbing the strong association of p50
and p65 for one another. Since DOC is known to dissociate I
B from
NF-
B (7), it was reasonable to assume that an I
B family member could be the nuclear inhibitor. However, Western blot
analysis failed to reveal the presence of known I
B family members in
Ad12-transformed cell nuclear extracts (38 and data not shown). To examine if another type of inhibitor might be present in
Ad12-transformed cell nuclear extracts, we performed a titration-mixing experiment in which increasing amounts of Ad12-transformed cell nuclear
extracts were added to a constant amount of Ad5-transformed cell
nuclear extracts and then analyzed by EMSA. As shown in Fig. 2, no reduction in the NF-
B binding
activity from Ad5-transformed cell nuclear extracts was observed (lanes
4 to 9), whereas the addition of recombinant I
B
(1 ng) was
sufficient to fully inhibit this activity (lane 3). Furthermore, blots
probed with a p50 antibody following gel filtration, nondenaturing gel
electrophoresis, or cross-linking of nuclear extracts did not reveal
size differences in NF-
B from Ad5- and Ad12-transformed cells (data
not shown). Thus, there was conflicting evidence for the presence of a
nuclear inhibitor of NF-
B in Ad12-transformed cells.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 2.
A freely dissociable inhibitor of NF- B is not present
in Ad12-transformed cell nuclear extracts. One microgram of
Ad5-transformed cell nuclear extracts (NE) was incubated in an EMSA
reaction alone (lane 2), with 1 ng of purified recombinant I B
(rI B ) (lane 3), or with increasing amounts (1, 2, 4, 8, 12, or 16 µg) of Ad12-transformed cell nuclear extracts (lanes 4 to 9),
followed by electrophoresis on a nondenaturing gel. The increased
binding activity in the titration curve (lanes 4 to 9) was largely
contributed by the increasing amounts of Ad12-transformed cell nuclear
extracts (compare lanes 1 and 10 [1 and 16 µg, respectively]).
Identical results were obtained when the total protein in each reaction
mixture was adjusted to 17 µg with BSA (data not shown). 50-50 homodimer and 50-65 heterodimer species are indicated. F, free R1 site
probe.
|
|
The block in NF-
B binding to DNA in Ad12-transformed cells does
not appear to involve a dissociable inhibitor.
To examine whether
or not a nuclear inhibitor is truly involved in the decreased DNA
binding activity of NF-
B in Ad12-transformed cells, we used a
denaturation-renaturation approach in which nuclear extracts from Ad5-
and Ad12-transformed cells were fractionated by PAGE and the p50 and
p65 subunits were excised from the gel, eluted, denatured, mixed
together, renatured, and subjected to EMSA. Restoration of binding of
denatured-renatured NF-
B from Ad12-transformed cells would indicate
the separation of an inhibitor from p50 and p65 during PAGE, whereas
nonrestoration of binding would be indicative of an alternative mechanism.
The EMSA in Fig.
3A indicated that
NF-

B binding remains diminished after denaturation-renaturation of
the p50 and p65 subunits
from Ad12- compared to Ad5-transformed cell
nuclear extracts.
Note that the differential binding activities
observed with the
denatured-renatured NF-

B proteins (Fig.
3A, lanes
3 and 4) are
similar to those seen with unmanipulated nuclear extracts
(lanes
1 and 2). This result suggested that there is not a dissociable
inhibitor of NF-

B in Ad12-transformed cell nuclear extracts.
This
low binding activity of denatured-renatured NF-

B from Ad12
was not
due to a lack of input of p50 and p65. First, Western
blotting
indicated that p50 and p65 were individually isolated
from the
polyacrylamide gel (Fig.
3A, lower panel) and subsequently
were
retained throughout the denaturation-renaturation procedure.
Second,
approximately equivalent amounts of the mixed and renatured
p50 and p65
subunits from Ad12- and Ad5-transformed cell nuclear
extracts were used
to obtain dimer compositions with ratios of
125I signals of
p65 and p50 similar to those from unmanipulated nuclear
extracts (data
not shown).



View larger version (151K):
[in this window]
[in a new window]
|
FIG. 3.
Denatured-renatured NF- B from Ad12-transformed cells
retains diminished binding activity. (A) Nuclear extracts (NE) from
Ad5- and Ad12-transformed cells were analyzed by EMSA either directly
(lanes 1 and 2) or following denaturation-renaturation (Den-Ren) of
gel-isolated 50- and 65-kDa proteins (lanes 3 and 4). (Lower panel)
Western analysis indicating retention of p50 and p65 during the
denaturation-renaturation procedure. (B) Nucleoprotein complexes from
denatured-renatured NF- B (lanes 7 to 12) mirrored those from nuclear
extracts (lanes 1 to 6) in a supershift analysis with p50 (1613) and
p65 (1226) antibodies (Ab). Overexposures of nucleoprotein complexes
from lanes 4 to 6 and 10 to 12 are shown in lanes 13 to 15 and 16 to
18, respectively. 50-50 homodimer, 50-65 heterodimer, and supershift
(SS) species are indicated. F, free R1 site probe.
|
|
To verify that the EMSA complexes generated from the samples of
denatured-renatured NF-

B (Fig.
3A) were truly composed of
p50 and
p65, a supershift analysis was performed. As shown in
Fig.
3B, for Ad5,
anti-p50 and anti-p65 antibodies were each able
to supershift NF-

B
from both unmanipulated nuclear extracts and
denatured-renatured
NF-

B (
33) (Fig.
3B, lanes 1 to 3 and 7
to 9). For Ad12,
these antibodies also shifted NF-

B from both
unmanipulated nuclear
extracts and denatured-renatured NF-

B (Fig.
3B, lanes 4 to 6 and 10 to 12), although the signal was dramatically
reduced, as expected.
These signals can be seen upon overexposure
(Fig.
3B, lanes 13 to 18).
Note that the increased binding activity
seen in the supershifts with
the anti-p50 antibody 1613 (Fig.
3B, lanes 2, 5, 8, 11, 14, and 17) is
likely due to a stabilization
effect.
Since these denaturation-renaturation experiments strongly suggested
that there is no dissociable protein inhibitor of NF-

B
in
Ad12-transformed cell nuclear extracts, we wished to investigate
the
action of DOC on denatured-renatured NF-

B by EMSA. Nuclear
proteins
from Ad12-transformed cells were separated by PAGE, and
p50 and p65
were isolated from the gel, denatured, and renatured
as described
above. EMSA reaction mixtures were incubated for
30 min, treated with
DOC, and analyzed on a nondenaturing gel
(Fig.
4). As described above, treatment of
unmanipulated Ad12-transformed
cell nuclear extracts with DOC resulted
in increased DNA binding
activity compared to that in untreated nuclear
extracts (Fig.
4, lanes 1 and 2). Interestingly, a marked increase in
this binding
activity was also observed when denatured-renatured
NF-

B was
treated with DOC (Fig.
4, lane 4), compared to the results
obtained
with the untreated sample (lane 3). Therefore, DOC treatment
likely
increases NF-

B binding to DNA in a manner distinct from the
dissociation
of a protein inhibitor (see below).

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 4.
Low binding activity of denatured-renatured NF- B from
Ad12-transformed cells is restored by DOC treatment. Nuclear extracts
(NE) (lanes 1 and 2) and denatured-renatured (Den-Ren) NF- B (lanes 3 and 4) from Ad12-transformed cells were subjected to EMSA following
treatment with DOC (lanes 2 and 4). Migration of the NF- B complex is
indicated (50/65). F, free R1 site probe.
|
|
These results demonstrated that it is possible to denature and
reconstitute NF-

B from nuclear extracts from Ad5- and
Ad12-transformed
cells. The integrity and composition of the
denatured-renatured
NF-

B used in the EMSAs are reflective of those
of native NF-

B
from unmanipulated nuclear extracts. The observation
that denatured-renatured
NF-

B from Ad12-transformed cell nuclear
extracts did not restore
binding to DNA supports the notion that a
dissociable inhibitor
of nuclear NF-

B is not present in
Ad12-transformed
cells.
Nuclear p50 from Ad12-transformed cells is responsible for
diminished NF-
B binding.
To further characterize the mechanism
responsible for the decreased binding of NF-
B in
Ad12-transformed cells, we sought to address if either p50 or p65 is functionally altered. To do so, we
again used denaturation-renaturation analysis of the p50 and p65
subunits from Ad5- and Ad12-transformed cell nuclear extracts. Hybrid
NF-
B dimers were created by mixing p50 from Ad5 with p65 from Ad12
and p50 from Ad12 with p65 from Ad5. Significantly, as shown in Fig.
5, the NF-
B-DNA complex containing
the dimer composed of p50 from Ad5 and p65 from Ad12 (lane 3)
recognized the labeled probe more strongly than did the complex
containing the dimer composed of p50 from Ad12 and p65 from Ad5 (lane
4). The differential binding activities observed with the hybrid dimers (Fig. 5, lanes 3 and 4) paralleled those observed with the
denatured-renatured dimers from Ad5- and Ad12-transformed cell nuclear
extracts (lanes 1 and 2). This result demonstrated that p50 is the
component of the p50-p65 heterodimer which is responsible for the
reduced binding of NF-
B to DNA in Ad12-transformed cell nuclear
extracts.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 5.
The p50 subunit contributes to the decreased DNA binding
activity of NF- B in Ad12-transformed cells. Lanes 1 and 2, denatured-renatured (Den-Ren) NF- B from Ad5- and Ad12-transformed
cell nuclear extracts, respectively. Lane 3, hybrid denatured-renatured
NF- B with p50 from Ad5-transformed cell nuclear extracts and p65
from Ad12-transformed cell nuclear extracts. Lane 4, hybrid
denatured-renatured NF- B with p50 from Ad12-transformed cell nuclear
extracts and p65 from Ad5-transformed cell nuclear extracts. 50-50 homodimers and 50-65 heterodimers are indicated. F, free R1 site
probe.
|
|
DOC can enhance NF-
B binding by affecting p65.
A caveat
with regard to the above results is that the decreased binding activity
of NF-
B from Ad12-transformed cell nuclear extracts is due to a
50-kDa "inhibitor" which fortuitously copurifies with the
p50-containing gel slice. Such a putative copurified inhibitor would be
stripped from NF-
B upon treatment of the nuclear extracts with DOC,
thereby restoring NF-
B binding to DNA. To address the possibility of
whether an inhibitor copurifies with p50, denatured-renatured p50
homodimers were treated with DOC and tested by EMSA to determine if
increased binding would occur. As shown in Fig.
6, DOC had no enhancing effect on the
binding activity of these homodimers from either Ad5- or
Ad12-transformed cell nuclear extracts (lanes 1 to 4), consistent with
the absence of a copurifying 50-kDa inhibitor in Ad12-transformed
cells. Quite unexpectedly, however, when denatured-renatured p65
homodimers from Ad5- and Ad12-transformed cell nuclear extracts were
similarly assayed, a noticeable increase in binding activity in the
presence of DOC was observed (Fig. 6, compare lane 5 with lane 6 and
compare lane 7 with lane 8). Supershift analysis confirmed that the
complexes observed in Fig. 6, lanes 5 to 8, contain p65 (data not
shown). Taken together, these results ruled out the possibility of a
proteinaceous inhibitor in Ad12-transformed cells and also suggested
that DOC restores NF-
B binding in Ad12-transformed cell nuclear
extracts through its action on the p65 subunit.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 6.
DOC enhances DNA binding by affecting p65.
Denatured-renatured homodimers of p50 (lanes 1 to 4) or p65 (lanes 5 to
8) from Ad5 (lanes 1, 2, 5, and 6)- and Ad12 (lanes 3, 4, 7, and
8)-transformed cell nuclear extracts were subjected to EMSA following
treatment with DOC (even-numbered lanes). The reduced signals in lanes
7 and 8 compared to those in lanes 5 and 6 were due to less
denatured-renatured p65 homodimer from Ad12 than from Ad5,
respectively, used in the EMSA as determined by quantitative Western
analysis. Migration of homodimers is indicated (50/50 and 65/65). F,
free R1 site probe.
|
|
p50 in Ad12- and Ad5-transformed cells is differentially
modified.
The denaturation-renaturation experiments indicated that
the diminished NF-
B binding activity seen in Ad12-transformed cells is likely due to an alteration of p50 in these cells. To determine if
Ad5- and Ad12-transformed cells harbor different forms of p50, nuclear
extracts were separated by two-dimensional gel electrophoresis followed
by Western blot analysis. As shown in Fig.
7, four major forms of p50 (species A to
D) were identified in both Ad5- and Ad12-transformed cell nuclear
extracts. These p50 species were authentic, as the antibody used (1157)
has absolute specificity, based on its inability to recognize any
50-kDa protein in p50
/
knockout mouse cell extracts
(52). Intriguingly, the signal from the most negatively
charged of the four forms of p50 (species A) was found to be weaker in
Ad12-transformed nuclear cell extracts than in Ad5-transformed cell
nuclear extracts. Densitometric analysis revealed that there was
approximately 4.5-fold less species A relative to the total amount of
p50 in Ad12- than in Ad5-transformed cell nuclear extracts. The
two-dimensional blot probed with a p65 antibody revealed no differences
in the forms of p65 from Ad12- and Ad5-transformed cell nuclear
extracts (data not shown).

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 7.
Two-dimensional gel analysis of charged p50 species from
Ad12- and Ad5-transformed cell nuclear extracts. Equivalent amounts of
protein from nuclear extracts (NE) of Ad5- and Ad12-transformed cells
were separated by two-dimensional gel electrophoresis, transferred to
polyvinylidene difluoride paper, and probed with p50 antibody (1157). A
to D, four major charged species of p50; the vertical arrow points to
species A. The horizontal arrow pointing to the oval near the negative
pole indicates the migration of the tropomyosin internal control,
visualized by Coomassie blue staining prior to immunoblotting. The pH
in the Western blots ranged from 4.8 (positive pole) to 8.9 (negative
pole).
|
|
The reduced level of p50 species A from Ad12-transformed cells in the
two-dimensional Western analysis suggested that p50
may be less
phosphorylated in these cells. To examine this possibility,
monolayer
cultures of Ad5- and Ad12-transformed cells were labeled
with
32P
i. Lysates normalized for counts were
subjected to sequential
immunoprecipitation analysis. Since the
absolutely specific anti-p50
antibody 1157 (described above) reacts
only against its denatured
epitope, a p50 antibody which recognizes
native p50 (1613) was
used to perform the primary immunoprecipitation.
The immunocomplexes
were then boiled and subjected to the second
immunoprecipitation
with the p50-specific antibody 1157. Notably, the
amount of
32P
i-labeled p50 recovered from
lysates of Ad5-transformed cells
was greater than that recovered from
Ad12-transformed cells (Fig.
8, lanes 1 and 2), whereas no difference in the signal from control
YY1 was
observed (lanes 3 and 4). The YY1 transcription factor
was chosen as a
control because extracts from both Ad5- and Ad12-transformed
cells
harbor it in nearly equivalent amounts, as observed by Western
analysis
and EMSA (data not shown). Not surprisingly, the reduced
level of
phosphorylation of p105 in Ad12- compared to Ad5-transformed
cells
(Fig.
8, lanes 1 and 2) can be attributed to the fact that
the p50
coding region is the N terminus of p105. In contrast,
no difference in
the level of phosphorylation of p65 was observed
(data not shown).
Thus, this differential level of phosphorylation
of p50 from Ad12- and
Ad5-transformed cells observed in the immunoprecipitation
analysis
correlates with the differential intensity of the most
negatively
charged form of p50, species A, seen in the Western
blot of the
two-dimensional gel (Fig.
7). This result is consistent
with the notion
that the low DNA binding activity of NF-

B in
Ad12-transformed cell
nuclear extracts stems from a modification
of p50, such as
phosphorylation, as opposed to the presence of
a dissociable inhibitor.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 8.
p50 is less phosphorylated in Ad12- than in
Ad5-transformed cells. Normalized lysates from
32Pi-labeled cells were subjected to sequential
immunoprecipitation (IP) with antibodies 1613 and 1157 (reactive to
native and denatured p50 epitopes, respectively) to detect
phosphorylated p50. The equal amounts of phosphorylated YY1 that were
immunoprecipitated from the two cell types verified that the
normalization of counts was accurate. The positions of labeled protein
species are indicated. The identity of the band (marked with an
asterisk) that cross-reacted with the YY1 antisera is unknown.
|
|
Phosphorylation of p50 contributes to DNA binding of NF-
B.
The experiments outlined above indicated that there may be a
correlation between the level of phosphorylation of p50 and the ability
of NF-
B to bind to DNA. To directly demonstrate that phosphorylation
of NF-
B is important for DNA binding, nuclear extracts from
Ad5-transformed cells (which contain hyperphosphorylated p50 and
strongly binding NF-
B) were isolated in the absence of phosphatase
inhibitors, either mock treated, CIP treated, or CIP treated in the
presence of phosphatase inhibitors, and then subjected to EMSA. As
shown in Fig. 9A, the endogenous NF-
B
binding activity observed in Ad5-transformed cell nuclear extracts
(lane 1) was ablated when extracts were CIP treated (lane 2) but was
unaltered when CIP was added to extracts containing phosphatase
inhibitors (lane 3), indicating that phosphorylation of NF-
B is
critical for DNA binding activity.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 9.
Phosphorylation of p50 is critical for NF- B binding
activity. (A) Dephosphorylation of NF- B ablates binding activity.
Nuclear extracts were untreated (lane 1) or treated with CIP in the
absence (lane 2) or presence (lane 3) of phosphatase inhibitors prior
to EMSA. (B) Phosphorylation of p50 specifically contributes to DNA
binding of NF- B. The denaturation-renaturation procedure included a
CIP treatment step after elution of the 50-kDa proteins from the
polyacrylamide gel. EMSA reaction mixtures contained NF- B with
CIP-treated p50 (lane 1) or CIP-treated p50 in the presence of
phosphatase inhibitors (lane 2) and untreated (phosphorylated) p65. F,
free R1 site probe.
|
|
To determine if phosphorylation of p50 specifically is responsible for
the ability of NF-

B to bind to DNA, the denaturation-renaturation
system was again used. Nuclear extracts from Ad5-transformed cells
were
isolated and fractionated by PAGE, and the p50 and p65 subunits
were
excised from the gel and eluted. The eluate containing p50
was halved,
treated with CIP or CIP in the presence of phosphatase
inhibitors, and
denatured. The p50 samples were mixed with the
denatured p65 subunit
which was not CIP treated. The mixed subunits
were renatured and
subjected to EMSA. Figure
9B shows that dephosphorylated
p50, when
present with phosphorylated p65, had dramatically reduced
DNA binding
activity (lane 1) compared to NF-

B in which p50 and
p65 were both
phosphorylated (lane 2). Interestingly, CIP treatment
of denatured p50
subunits inhibited the formation of p50 homodimers
following
renaturation (data not shown). Therefore, phosphorylation
of p50 is
required for optimal DNA binding activity of NF-

B.
 |
DISCUSSION |
Diminished surface expression of the MHC class I antigens
contributes to the tumorigenic potential of transformed cells by enabling them to evade immune detection by CTL. The tumorigenicity of
Ad12-transformed cells correlates with decreased MHC class I expression
(11, 17, 59, 70). In these cells, E1A mediates down-regulation of MHC class I transcription by increasing the binding
of the repressor COUP-TF and decreasing the binding of the activator
NF-
B to the class I enhancer (2, 38, 39, 43, 46).
At the onset of this study, there were conflicting arguments to account
for the mechanism by which NF-
B is blocked from binding to the R1
site of the class I enhancer in Ad12-transformed cells. In one case,
the presence of a nuclear inhibitor was suggested by the restoration of
NF-
B binding to DNA following treatment of nuclear extracts with the
detergent DOC. However, Ad12-transformed cell nuclear extracts failed
to transinhibit the strong NF-
B binding in Ad5-transformed cell
nuclear extracts, leading us to question the existence of a nuclear
inhibitor and suggesting that NF-
B could be differentially modified
in Ad12-transformed cells.
In this study, we used a variety of biochemical approaches to establish
that in Ad12-transformed cells, decreased binding of NF-
B is related
to a modification of the p50 subunit and is not due to a nuclear
inhibitor. In addition, hypophosphorylation of p50 correlates with
restricted binding of NF-
B to DNA (Fig. 10). Furthermore, the enhanced binding
of NF-
B to DNA in the presence of DOC is due to an effect of the
detergent on the p65 subunit of NF-
B. These findings therefore not
only aid in the understanding of the mechanism responsible for the
block of NF-
B binding to the class I enhancer in Ad12-transformed
cells but also suggest that p50 phosphorylation is critical for NF-
B
binding to DNA.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 10.
Model showing that NF- B containing
hypophosphorylated p50 has a reduced ability to bind to DNA in
Ad12-transformed cells. In contrast, in Ad5-transformed cells, NF- B
containing hyperphosphorylated p50 actively binds to DNA. The black
oval in p65 represents its transactivation domain.
|
|
To the best of our knowledge, our study is the first demonstration that
p50 phosphorylation is important for NF-
B binding. This conclusion
is based largely on the observation that dephosphorylation of the p50
subunit isolated from Ad5-transformed cell nuclear extracts impairs the
ability of reconstituted NF-
B to bind to DNA. Consistent with this
requirement for p50 phosphorylation for p50-p65 NF-
B heterodimer
binding, Li et al. have shown that the in vitro phosphorylation of
bacterially produced p50 by protein kinase C results in the enhancement
of p50 homodimer binding to DNA (35).
It is important to consider how differential phosphorylation of p50
affects the ability of NF-
B to bind to DNA in Ad12-transformed cells. One possibility is that reduced p50 phosphorylation inhibits dimerization. However, equivalent amounts of p65 were
coimmunoprecipitated with p50 in both Ad12- and Ad5-transformed cells
(34). This result indicates that the decreased
phosphorylation of p50 in Ad12-transformed cells does not impair
dimerization but rather inhibits binding of the dimer to DNA. It is
also important to question if p65 is differentially modified in Ad12-
versus Ad5-transformed cells. Three pieces of evidence suggest that p65
is not differentially altered. First, identical species of p65 were
observed in the two-dimensional gels of Ad12- and Ad5-transformed cell
nuclear extracts (34). Second, a hybrid NF-
B composed of
p65 from Ad12 and p50 from Ad5 strongly bound to DNA. Finally, the
transactivation domain of p65 is not functionally impaired or inhibited
in Ad12-transformed cells, since a transfected Gal4-p65 transactivation
domain was able to transactivate a promoter containing Gal4 DNA binding
sites (34). These results indicate that in Ad12- versus
Ad5-transformed cells, p50, but not p65, is differentially modified and
that this modification reduces the ability of NF-
B to bind to DNA.
While phosphorylation of p50 is critical for the binding of NF-
B to
DNA as shown in this study, phosphorylation of p65 was recently shown
to be important for NF-
B transactivation (71). Phosphorylation of p65 by protein kinase A allows p65 to unfold and
interact with p300 in order to transactivate (71). In
Ad12-transformed cells, unfolded and transcriptionally potent p65
dimerized with hypophosphorylated p50 would be unable to transactivate,
as the NF-
B heterodimer cannot bind to DNA. Therefore, the
phosphostatus of p50 may be critical in the ultimate ability of NF-
B
to transactivate. Indeed, unlike p50 homodimers and the NF-
B
heterodimer, p65 homodimers do not readily bind to DNA. Significantly,
the recent elucidation of the DNA-bound NF-
B crystal structure
(13) also indicates the importance of p50 making fixed
contacts with a specific DNA sequence, 5'-GGGRN-3'. Perhaps
phosphorylation of p50 alters its conformation to facilitate
interaction with these key nucleotides. The observation that p65 has
less rigorous requirements for specific residues for DNA interaction
adds to the notion that p50 is important for enabling NF-
B to bind
to DNA.
An interesting observation of this study is the indication that DOC
acts directly on p65 to enhance NF-
B binding. One explanation is
that detergent binding induces swelling or a conformational alteration
of p65 which consequently facilitates the DNA binding ability of
NF-
B. Intriguingly, upon binding to purified calf brain tubulin, DOC
has been shown to expand the protein, as examined by sedimentation,
circular dichroism, and synchrotron X-ray scattering analyses
(4-6). Interestingly, Zhong and colleagues recently observed that the N and C termini of p65 intramolecularly interact until phosphorylated at serine 276 by protein kinase A, which opens the
protein and enhances DNA binding of NF-
B (71). DOC may
relieve this intramolecular interaction in p65, enhancing NF-
B
binding. Indeed, we have observed that the enhanced binding of NF-
B
to DNA in the presence of DOC is not limited to Ad12-transformed cell
nuclear extracts but that DOC further increases the strong binding
activity of NF-
B in nuclear extracts from Ad5- and simian virus
40-transformed cells (40). Perhaps in addition to opening p65, DOC acts in some manner to permit NF-
B binding activity to
occur independently of the phosphostatus of p50. Notably, the ability
of DOC to release I
B from NF-
B (7) may not be mutually exclusive of the possibility that DOC has the ability to disrupt the
intramolecular association of p65 termini. Whether or not DOC has this
effect on other transcription factors should be considered, as this
detergent is commonly used to characterize multiprotein-DNA complexes
by EMSA.
Multiple phosphorylation events have been shown to be critical in the
regulation of members of the Rel/NF-
B family (reviewed in reference
19). Identification of the p50 phosphorylation sites
and relevant kinases or phosphatases will enhance understanding of how
the binding of NF-
B is regulated. Initial phosphopeptide mapping
studies indicate that p50 is serine phosphorylated in primary T
lymphocytes (25) and in phorbol myristate acetate- and
phytohemagglutinin-stimulated Jurkat T cells (36), although other investigators have been unable to detect
32Pi-labeled p50 in stimulated Jurkat T cells
by immunoprecipitation (41). We clearly can recover
32Pi-labeled p50 from Ad5-transformed cells and
can observe a faint signal from Ad12-transformed cells. Interestingly,
Ad5 E1A has been shown to be associated with a serine/threonine kinase
composed of cyclin E-p33cdk2 and cyclin
A-p33cdk2 (18, 26, 31). The former
kinase has been shown to be associated with p65 via the E1A-associated
coactivator p300 (53), but it is unclear if this kinase is
specific for p50. Perhaps the decreased phosphorylation of p50 in
Ad12-transformed cells results from inhibition of a kinase activity
mediated by the Ad12 E1A protein. Alternatively, the possibility that a
phosphatase acts on p50 exclusively in Ad12-transformed cells cannot be
excluded. Additional regulatory complexity may result from the numerous
protein interactions among E1A, p300, and p65. For example, both p300
and Ad5 E1A have been shown to interact with the C terminus of p65
(22, 49, 53). It has also been shown that an
amino-terminally modified Ad12 E1A which fails to interact with p300
exists (68). In addition, p300 itself is differentially
phosphorylated in Ad12 E1- versus Ad5 E1-transformed cells
(51). Whether any of these interactions is significant in
terms of regulation of NF-
B via p50 phosphorylation remains to be determined.
 |
ACKNOWLEDGMENTS |
We thank Nancy Rice for helpful discussions and for Rel family
antibodies, Tom Kadesch for valuable suggestions, Rebecca Taub for
recombinant I
B
, and Patrick Baeuerle for Gal4-p65 plasmids. We
thank members of the Ricciardi laboratory for critical reading of the
manuscript. We also thank Holly Hans, Noam Harel, Chuck Whitbeck, and
Sharon Willis for technical advice.
This work was supported in part by NIH training grant 5-T32-AI0735 (to
D.B.K.) and by NIH grant CA29797 (to R.P.R.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Pennsylvania, Levy Research Building, Room 221, 4010 Locust St.,
Philadelphia, PA 19104. Phone: 215-898-3905. Fax: 215-898-8385. E-mail:
ricciardi{at}biochem.dental.upenn.edu.
Present address: Institute for Molecular Virology, University of
Wisconsin
Madison, Madison, WI 53706.
 |
REFERENCES |
| 1.
|
Ackrill, A. M., and G. E. Blair.
1988.
Regulation of major histocompatibility class I gene expression at the level of transcription in highly oncogenic adenovirus transformed rat cells.
Oncogene
3:483-487[Medline].
|
| 2.
|
Ackrill, A. M., and G. E. Blair.
1989.
Nuclear proteins binding to an enhancer element of the major histocompatibility complex promoter: differences between highly oncogenic and nononcogenic adenovirus-transformed rat cells.
Virology
172:643-646[Medline].
|
| 3.
|
Alkalay, I.,
A. Yaron,
A. Hatzubai,
S. Jung,
A. Avraham,
O. Gerlitz,
I. Pashut-Lavon, and Y. Ben-Neriah.
1995.
In vivo stimulation of I B phosphorylation is not sufficient to activate NF- B.
Mol. Cell. Biol.
15:1294-1301[Abstract].
|
| 4.
|
Andreu, J. M.,
J. de la Torre, and J. L. Carrascosa.
1986.
Interaction of tubulin with octyl glucoside and deoxycholate. 2. Protein conformation, binding of colchicine ligands, and microtubule assembly.
Biochemistry
25:5230-5239[Medline].
|
| 5.
|
Andreu, J. M.,
J. Garcia de Ancos,
D. Starling,
J. L. Hodgkinson, and J. Bordas.
1989.
A synchrotron X-ray scattering characterization of purified tubulin and of its expansion induced by mild detergent binding.
Biochemistry
28:4036-4040[Medline].
|
| 6.
|
Andreu, J. M., and J. A. Muñoz.
1986.
Interaction of tubulin with octyl glucoside and deoxycholate. 1. Binding and hydrodynamic studies.
Biochemistry
25:5220-5230[Medline].
|
| 7.
|
Baeuerle, P. A., and D. Baltimore.
1988.
Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF- B transcription factor.
Cell
53:211-217[Medline].
|
| 8.
|
Baeuerle, P. A., and D. Baltimore.
1996.
NF- B: ten years after.
Cell
87:13-20[Medline].
|
| 9.
|
Baldwin, A. S., Jr., and P. A. Sharp.
1988.
Two transcription factors, NF- B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter.
Proc. Natl. Acad. Sci. USA
85:723-727[Abstract/Free Full Text].
|
| 10.
|
Ballard, D. W.,
E. P. Nixon,
N. J. Peffer,
H. Bogerd,
S. Doerre,
B. Stein, and W. C. Greene.
1992.
The 65-kDa subunit of human NF- B functions as a potent transcriptional activator and a target for v-Rel-mediated repression.
Proc. Natl. Acad. Sci. USA
89:1875-1879[Abstract/Free Full Text].
|
| 11.
|
Bernards, R.,
P. I. Schrier,
A. Houweling,
J. L. Bos,
A. J. van der Eb,
M. Zijlstra, and C. J. Melief.
1983.
Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity.
Nature (London)
305:776-779[Medline].
|
| 12.
|
Bours, V.,
J. Villalobos,
P. R. Burd,
K. Kelly, and U. Siebenlist.
1990.
Cloning of a mitogen-inducible gene encoding a B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs.
Nature (London)
348:76-80[Medline].
|
| 13.
|
Chen, F. E.,
D.-B. Huang,
Y.-Q. Chen, and G. Ghosh.
1998.
Crystal structure of p50/p65 heterodimer of transcription factor NF- B bound to DNA.
Nature
391:410-413[Medline].
|
| 14.
|
Chen, Z.,
J. Hagler,
V. J. Palombella,
F. Melandri,
D. Scherer,
D. Baltimore, and T. Maniatis.
1995.
Signal-induced site-specific phosphorylation targets I B to the ubiquitin-proteasome pathway.
Genes Dev.
9:1586-1597[Abstract/Free Full Text].
|
| 15.
|
DiDonato, J. A.,
F. Mercurio, and M. Karin.
1995.
Phosphorylation of I B precedes but is not sufficient for its dissociation from NF- B.
Mol. Cell. Biol.
15:1302-1311[Abstract].
|
| 16.
|
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 17.
|
Eager, K. B.,
J. Williams,
D. Breiding,
S. Pan,
B. Knowles,
E. Appella, and R. P. Ricciardi.
1985.
Expression of histocompatibility antigens H-2K, -D, and -L is reduced in adenovirus-12-transformed mouse cells and is restored by interferon- .
Proc. Natl. Acad. Sci. USA
82:5525-5529[Abstract/Free Full Text].
|
| 18.
|
Faha, B.,
E. Harlow, and E. Lees.
1993.
The adenovirus E1A-associated kinase consists of cyclin E-p33cdk2 and cyclin A-p33cdk2.
J. Virol.
67:2456-2465[Abstract/Free Full Text].
|
| 19.
|
Finco, T. S., and A. S. Baldwin, Jr.
1995.
Mechanistic aspects of NF- B regulation: the emerging role of phosphorylation and proteolysis.
Immunity
3:263-272[Medline].
|
| 20.
|
Friedman, D. J., and R. P. Ricciardi.
1988.
Adenovirus type 12 E1A gene represses accumulation of MHC class I mRNAs at the level of transcription.
Virology
165:303-305[Medline].
|
| 21.
|
Ge, R.,
A. Kralli,
R. Weinmann, and R. P. Ricciardi.
1992.
Down-regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells is accompanied by an increase in factor binding.
J. Virol.
66:6969-6978[Abstract/Free Full Text].
|
| 22.
|
Gerritsen, M. E.,
A. J. Williams,
A. S. Neish,
S. Moore,
Y. Shi, and T. Collins.
1997.
CREB-binding protein/p300 are transcriptional coactivators of p65.
Proc. Natl. Acad. Sci. USA
94:2927-2932[Abstract/Free Full Text].
|
| 23.
|
Ghosh, S.,
A. M. Gifford,
L. R. Riviere,
P. Tempst,
G. P. Nolan, and D. Baltimore.
1990.
Cloning of the p50 DNA-binding subunit of NF- B: homology to rel and dorsal.
Cell
62:1019-1029[Medline].
|
| 24.
|
Hager, D. A., and R. R. Burgess.
1980.
Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes.
Anal. Biochem.
109:76-86[Medline].
|
| 25.
|
Hayashi, T.,
T. Sekine, and T. Okamoto.
1993.
Identification of a new serine kinase that activates NF- B by direct phosphorylation.
J. Biol. Chem.
268:26790-26795[Abstract/Free Full Text].
|
| 26.
|
Herrmann, C. H.,
L.-K. Su, and E. Harlow.
1991.
Adenovirus E1A is associated with a serine/threonine protein kinase.
J. Virol.
65:5848-5859[Abstract/Free Full Text].
|
| 27.
|
Israël, A.,
O. Le Bail,
D. Hatat,
J. Piette,
M. Kieran,
F. Logeat,
D. Wallach,
M. Fellous, and P. Kourilsky.
1989.
TNF stimulates expression of mouse MHC class I genes by inducing an NF- B-like enhancer binding activity which displaces constitutive factors.
EMBO J.
8:3793-3800[Medline].
|
| 28.
|
Jelinek, T., and F. L. Graham.
1992.
Recombinant human adenoviruses containing hybrid adenovirus type 5 (Ad5)/Ad12 E1A genes: characterization of hybrid E1A proteins and analysis of transforming activity and host range.
J. Virol.
66:4117-4125[Abstract/Free Full Text].
|
| 29.
|
Jelinek, T.,
D. S. Pereira, and F. L. Graham.
1994.
Tumorigenicity of adenovirus-transformed rodent cells is influenced by at least two regions of adenovirus type 12 early region 1A.
J. Virol.
68:888-896[Abstract/Free Full Text].
|
| 30.
|
Kieran, M.,
V. Blank,
F. Logeat,
J. Vanderkerckhove,
F. Lottspeich,
O. Le Bail,
M. B. Urban,
P. Kourilsky,
P. A. Baeuerle, and A. Israël.
1990.
The DNA binding subunit of NF- B is identical to factor KBF1 and homologous to the rel oncogene product.
Cell
62:1007-1018[Medline].
|
| 31.
|
Kleinberger, T., and T. Shenk.
1991.
A protein kinase is present in a complex with adenovirus E1A proteins.
Proc. Natl. Acad. Sci. USA
88:11143-11147[Abstract/Free Full Text].
|
| 32.
|
Kralli, A.,
R. Ge,
U. Graeven,
R. P. Ricciardi, and R. Weinmann.
1992.
Negative regulation of the major histocompatibility complex enhancer in adenovirus type 12-transformed cells via a retinoic acid response element.
J. Virol.
68:6979-6988.
|
| 33.
|
Kushner, D. B.,
D. S. Pereira,
X. Liu,
F. L. Graham, and R. P. Ricciardi.
1996.
The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF- B to the MHC class I enhancer in transformed cells.
Oncogene
12:143-151[Medline].
|
| 34.
| Kushner, D. B., and R. P. Ricciardi.
Unpublished observations.
|
| 35.
|
Li, C.-C. H.,
R.-M. Dai,
E. Chen, and D. L. Longo.
1994.
Phosphorylation of NF- B1-p50 is involved in NF- B activation and stable DNA binding.
J. Biol. Chem.
269:30089-30092[Abstract/Free Full Text].
|
| 36.
|
Li, C.-C. H.,
M. Korner,
D. K. Ferris,
E. Chen,
R.-M. Dai, and D. L. Longo.
1994.
NF- B/Rel family members are physically associated phosphoproteins.
Biochem. J.
303:499-506.
|
| 37.
|
Lin, Y. C.,
K. Brown, and U. Siebenlist.
1995.
Activation of NF- B requires proteolysis of the inhibitor I B- : signal-induced phosphorylation of I B- alone does not release active NF- B.
Proc. Natl. Acad. Sci. USA
92:552-556[Abstract/Free Full Text].
|
| 38.
|
Liu, X.,
R. Ge, and R. P. Ricciardi.
1996.
Evidence for the involvement of a nuclear NF- B inhibitor in global down-regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells.
Mol. Cell. Biol.
16:398-404[Abstract].
|
| 39.
|
Liu, X.,
R. Ge,
S. Westmoreland,
A. J. Cooney,
S. Y. Tsai,
M.-J. Tsai, and R. P. Ricciardi.
1994.
Negative regulation by the R2 element of the MHC class I enhancer in adenovirus-12 transformed cells correlates with high levels of COUP-TF binding.
Oncogene
9:2183-2190[Medline].
|
| 40.
| Liu, X., D. B. Kushner, and R. P. Ricciardi. Unpublished results.
|
| 41.
|
MacKichan, M. L.,
F. Logeat, and A. Israël.
1996.
Phosphorylation of p105 PEST sequences via a redox-insensitive pathway up-regulates processing to p50 NF- B.
J. Biol. Chem.
271:6084-6091[Abstract/Free Full Text].
|
| 42.
|
May, M. J., and S. Ghosh.
1997.
Rel/NF- B and I B proteins: an overview.
Semin. Cancer Biol.
8:63-73[Medline].
|
| 43.
|
Meijer, I.,
A. J. M. Boot,
G. Mahabir,
A. Zantema, and A. J. van der Eb.
1992.
Reduced binding activity of transcription factor NF- B accounts for MHC class I repression in adenovirus type 12 E1-transformed cells.
Cell. Immunol.
145:56-65[Medline].
|
| 44.
|
Meyer, R.,
E. N. Hatada,
H. P. Hohmann,
M. Haiker,
C. Bartsch,
U. Rothlisberger,
H. W. Lahm,
E. J. Schlaeger,
A. P. G. M. van Loon, and C. Scheidereit.
1991.
Cloning of the DNA-binding subunit of human nuclear factor B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor .
Proc. Natl. Acad. Sci. USA
88:966-970[Abstract/Free Full Text].
|
| 45.
|
Miyamoto, S., and I. M. Verma.
1995.
Rel/NF- B/I B story.
Adv. Cancer Res.
66:255-292[Medline].
|
| 46.
|
Nielsch, U.,
S. G. Zimmer, and L. E. Babiss.
1991.
Changes in NF- B and ISGF3 DNA binding activities are responsible for differences in MHC and -IFN gene expression in Ad5- versus Ad12-transformed cells.
EMBO J.
10:4169-4175[Medline].
|
| 47.
|
Nolan, G. P.,
S. Ghosh,
H. C. Liou,
P. Tempst, and D. Baltimore.
1991.
DNA binding and I B inhibition of the cloned p65 subunit of NF- B, a rel-related polypeptide.
Cell
64:961-969[Medline].
|
| 48.
|
O'Farrell, P. H.
1975.
High resolution two-dimensional electrophoresis of proteins.
J. Biol. Chem.
250:4007-4021[Abstract/Free Full Text].
|
| 49.
|
Paal, K.,
P. A. Baeuerle, and M. L. Schmitz.
1997.
Basal transcription factors TBP and TFIIB and the viral coactivator E1A 13S bind with distinct affinities and kinetics to the transactivation domain of NF- B p65.
Nucleic Acids Res.
25:1050-1055[Abstract/Free Full Text].
|
| 50.
|
Palombella, V. J.,
O. J. Rando,
A. L. Goldberg, and T. Maniatis.
1994.
The ubiquitin-proteasome pathway is required for processing the NF- B1 precursor protein and the activation of NF- B.
Cell
78:773-785[Medline].
|
| 51.
|
Pereira, D. S.,
T. Jelinek, and F. L. Graham.
1994.
The adenovirus E1A-associated p300 protein is differentially phosphorylated in Ad12 E1A- compared to Ad5 E1A-transformed rat cells.
Int. J. Oncol.
5:1197-1205.
|
| 52.
|
Pereira, D. S.,
D. B. Kushner,
R. P. Ricciardi, and F. L. Graham.
1996.
Testing NF- B1-p50 antibody specificity using knockout mice.
Oncogene
13:445-446[Medline].
|
| 53.
|
Perkins, N. D.,
L. K. Felzien,
J. C. Betts,
K. Leung,
D. H. Beach, and G. J. Nabel.
1997.
Regulation of NF- B by cyclin-dependent kinases associated with the p300 coactivator.
Science
275:523-527[Abstract/Free Full Text].
|
| 54.
|
Perkins, N. D.,
R. M. Schmid,
C. S. Duckett,
K. Leung,
N. R. Rice, and G. J. Nabel.
1992.
Distinct combinations of NF- B subunits determine the specificity of transcriptional activation.
Proc. Natl. Acad. Sci. USA
89:1529-1533[Abstract/Free Full Text].
|
| 55.
|
Plaksin, D.,
P. A. Baeuerle, and L. Eisenbach.
1993.
KBF1 (p50 NF- B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells.
J. Exp. Med.
177:1651-1662[Abstract/Free Full Text].
|
| 56.
| Ricciardi, R. P. Adenovirus transformation and
tumorigenicity. In P. Seth (ed.), Adenoviruses: from basic
research to gene therapy applications, in press. Landes Publishing,
Georgetown, Tex.
|
| 57.
|
Ruben, S. M.,
P. J. Dillon,
R. Schreck,
T. Henkel,
C.-H. Chen,
M. Maher,
P. A. Baeuerle, and C. A. Rosen.
1991.
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF- B.
Science
251:1490-1493[Abstract/Free Full Text].
|
| 58.
|
Schmitz, M. L., and P. A. Baeuerle.
1991.
The p65 subunit is responsible for the strong activating potential of NF- B.
EMBO J.
10:3805-3817[Medline].
|
| 59.
|
Schrier, P. I.,
R. Bernards,
R. T. M. J. Vaessen,
A. Houweling, and A. J. van der Eb.
1983.
Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells.
Nature (London)
305:771-775[Medline].
|
| 60.
|
Segars, J. H.,
T. Nagata,
V. Bours,
J. A. Medin,
G. Franzoso,
J. C. G. Blanco,
P. D. Drew,
K. G. Becker,
J. An,
T. Tang,
D. A. Stephany,
B. Neel,
U. Siebenlist, and K. Ozato.
1993.
Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF- B (p50-p65) and retinoic acid receptor -retinoid X receptor heterodimers.
Mol. Cell. Biol.
13:6157-6169[Abstract/Free Full Text].
|
| 61.
|
Shapiro, D. J.,
P. A. Sharp,
W. W. Wahli, and M. J. Keller.
1988.
A high-efficiency HeLa cell nuclear transcription extract.
DNA
7:47-55[Medline].
|
| 62.
|
Stancovski, I., and D. Baltimore.
1997.
NF- B activation: the I B kinase revealed?
Cell
91:299-302[Medline].
|
| 63.
|
Tanaka, K.,
K. J. Isselbacher,
G. Khoury, and G. Jay.
1985.
Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene.
Science
228:26-30[Abstract/Free Full Text].
|
| 64.
|
Thanos, D., and T. Maniatis.
1995.
NF- B: a lesson in family values.
Cell
80:529-532[Medline].
|
| 65.
|
Traenckner, E. B.-M.,
S. Wilk, and P. A. Baeuerle.
1994.
A proteasome inhibitor prevents activation of NF- B and stabilizes a newly phosphorylated form of I B that is still bound to NF- B.
EMBO J.
13:5433-5441[Medline].
|
| 66.
|
Urban, M. B.,
R. Schreck, and P. A. Baeuerle.
1991.
NF- B contacts DNA by a heterodimer of the p50 and p65 subunit.
EMBO J.
10:1817-1825[Medline].
|
| 67.
|
Vasavada, R.,
K. B. Eager,
G. Barbanti-Brodano,
A. Caputo, and R. P. Ricciardi.
1986.
Adenovirus type 12 early region 1A proteins repress class I HLA expression in transformed human cells.
Proc. Natl. Acad. Sci. USA
83:5257-5261[Abstract/Free Full Text].
|
| 68.
|
Wang, H.-G. H.,
P. Yaciuk,
R. P. Ricciardi,
M. Green,
K. Yokoyama, and E. Moran.
1993.
The E1A products of oncogenic adenovirus serotype 12 include amino-terminally modified forms able to bind to the retinoblastoma protein but not p300.
J. Virol.
67:4804-4813[Abstract/Free Full Text].
|
| 69.
|
Whiteside, S. T., and A. Israël.
1997.
I B proteins: structure, function, and regulation.
Semin. Cancer Biol.
8:75-82[Medline].
|
| 70.
|
Yewdell, J. W.,
J. R. Bennink,
K. B. Eager, and R. P. Ricciardi.
1988.
CTL recognition of adenovirus-transformed cells infected with influenza virus: lysis by anti-influenza CTL parallels adenovirus-12-induced suppression of class I MHC molecules.
Virology
162:236-238[Medline].
|
| 71.
|
Zhong, H.,
R. E. Voll, and S. Ghosh.
1998.
Phosphorylation of NF- B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300.
Molec. Cell
1:661-671[Medline].
|
Molecular and Cellular Biology, March 1999, p. 2169-2179, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Guan, H., Williams, J. F., Ricciardi, R. P.
(2009). Induction of Neuronal and Tumor-Related Genes by Adenovirus Type 12 E1A. J. Virol.
83: 651-661
[Abstract]
[Full Text]
-
Guan, H., Jiao, J., Ricciardi, R. P.
(2008). Tumorigenic Adenovirus Type 12 E1A Inhibits Phosphorylation of NF-{kappa}B by PKAc, Causing Loss of DNA Binding and Transactivation. J. Virol.
82: 40-48
[Abstract]
[Full Text]
-
Guan, H., Hou, S., Ricciardi, R. P.
(2005). DNA Binding of Repressor Nuclear Factor-{kappa}B p50/p50 Depends on Phosphorylation of Ser337 by the Protein Kinase A Catalytic Subunit. J. Biol. Chem.
280: 9957-9962
[Abstract]
[Full Text]
-
Chen, F.
(2004). Endogenous Inhibitors of Nuclear Factor-{kappa}B, An Opportunity for Cancer Control. Cancer Res.
64: 8135-8138
[Abstract]
[Full Text]
-
Chen, X., Lin, K., Ricciardi, R. P.
(2004). Human Kaposi's Sarcoma Herpesvirus Processivity Factor-8 Functions as a Dimer in DNA Synthesis. J. Biol. Chem.
279: 28375-28386
[Abstract]
[Full Text]
-
Hou, S., Guan, H., Ricciardi, R. P.
(2003). Phosphorylation of Serine 337 of NF-{kappa}B p50 Is Critical for DNA Binding. J. Biol. Chem.
278: 45994-45998
[Abstract]
[Full Text]
-
Morris, K. R., Lutz, R. D., Choi, H.-S., Kamitani, T., Chmura, K., Chan, E. D.
(2003). Role of the NF-{kappa}B Signaling Pathway and {kappa}B cis-Regulatory Elements on the IRF-1 and iNOS Promoter Regions in Mycobacterial Lipoarabinomannan Induction of Nitric Oxide. Infect. Immun.
71: 1442-1452
[Abstract]
[Full Text]
-
Vertegaal, A. C. O., Kuiperij, H. B., Houweling, A., Verlaan, M., van der Eb, A. J., Zantema, A.
(2003). Differential Expression of Tapasin and Immunoproteasome Subunits in Adenovirus Type 5- Versus Type 12-transformed Cells. J. Biol. Chem.
278: 139-146
[Abstract]
[Full Text]
-
Liu, C.-j., Ding, B., Wang, H., Lengyel, P.
(2002). The MyoD-Inducible p204 Protein Overcomes the Inhibition of Myoblast Differentiation by Id Proteins. Mol. Cell. Biol.
22: 2893-2905
[Abstract]
[Full Text]
-
Hou, S., Guan, H., Ricciardi, R. P.
(2002). In Adenovirus Type 12 Tumorigenic Cells, Major Histocompatibility Complex Class I Transcription Shutoff Is Overcome by Induction of NF-{kappa}B and Relief of COUP-TFII Repression. J. Virol.
76: 3212-3220
[Abstract]
[Full Text]
-
Frost, J. A., Swantek, J. L., Stippec, S., Yin, M. J., Gaynor, R., Cobb, M. H.
(2000). Stimulation of NFkappa B Activity by Multiple Signaling Pathways Requires PAK1. J. Biol. Chem.
275: 19693-19699
[Abstract]
[Full Text]